%0 Journal Article
%T ER¦Á Gene Promoter Methylation in Cognitive Function and Quality of Life of Patients With Alzheimer Disease
%A Guang-Hui Du
%A Jun-Kang Wang
%A Kai-Xiu Li
%A Ling-Ling Wei
%A Qin Sun
%A Xue Huang
%J Journal of Geriatric Psychiatry and Neurology
%@ 1552-5708
%D 2019
%R 10.1177/0891988719835325
%X Alzheimer disease (AD) has been recognized as a progressive neurodegenerative disorder. This study aims to investigate the effects of estrogen receptor ¦Á (ER¦Á) gene promoter methylation on the cognitive function and quality of life (QOL) of patients with AD. A total of 132 patients with AD and 135 healthy individuals were recruited for this study. The DNA in the peripheral blood was extracted and treated with bisulfite; then methylation-specific polymerase chain reaction and reverse transcription quantitative polymerase chain reaction were performed to determine the methylation status of ER¦Á and ER¦Á messenger RNA (mRNA) expression, respectively. Mini-Mental State Examination (MMSE), activities of daily living (ADL), and Quality of Life¨CAlzheimer Disease scale were employed to evaluate the cognitive functions, ADL, and QOL of the participants. The methylation group showed a decrease in ER¦Á mRNA expression. The MMSE and ADL scores were indicative of a worse cognitive function in the methylation group. The ER¦Á promoter methylated patients showed a higher rate of abnormal ADL score, while patients in the nonmethylation group enjoyed a better QOL. The ER¦Á promoter methylation is related to impaired cognitive function and QOL of patients with AD by inhibiting ER¦Á mRNA expression and transcription
%K estrogen receptor ¦Á
%K Alzheimer disease
%K promoter methylation
%K cognitive function
%K quality of life
%U https://journals.sagepub.com/doi/full/10.1177/0891988719835325